

ForPatients

by Roche

Duchenne Muscular Dystrophy (DMD)

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

Trial Status
Recruiting

Trial Runs In
6 Countries

Trial Identifier
NCT06128564 2022-000691-19
BN43881

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT06128564 2022-000691-19 BN43881
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
<= 3 Years

Healthy Volunteers
No
